{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:23:24Z","timestamp":1777073004655,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1151153"],"award-info":[{"award-number":["OPP1151153"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We assessed anti-Vi IgG\/IgA responses to typhoid conjugate vaccine (TCV) in children enrolled in a double-blind randomized controlled, phase 2 trial in Burkina Faso. Anti-Vi IgG seroconversion and anti-Vi IgA titers were higher in TCV than control recipients at 30\u201335 months post-vaccination. TCV induces durable immunity in Burkinabe children vaccinated at 15 months.<\/jats:p>","DOI":"10.1093\/jpids\/piad058","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:42:58Z","timestamp":1692290578000},"page":"513-518","source":"Crossref","is-referenced-by-count":8,"title":["Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso"],"prefix":"10.1093","volume":"12","author":[{"given":"Alphonse","family":"Ouedraogo","sequence":"first","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 , Ouagadougou , Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amidou","family":"Diarra","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 , Ouagadougou , Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"N\u00e9bi\u00e9","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 , Ouagadougou , Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouhoun","family":"Barry","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 , Ouagadougou , Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Moise","family":"Kabore","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 , Ouagadougou , Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred B","family":"Tiono","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 , Ouagadougou , Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrimati","family":"Datta","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Liang","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"},{"name":"Department of Epidemiology and Public Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifayet","family":"Mayo","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J","family":"Oshinsky","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Kathleen","family":"Tracy","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsion","family":"Girmay","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela F","family":"Pasetti","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4997-4570","authenticated-orcid":false,"given":"Leslie P","family":"Jamka","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M","family":"Neuzil","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sodiomon B","family":"Sirima","sequence":"additional","affiliation":[{"name":"Groupe de Recherche Action en Sant\u00e9 , Ouagadougou , Burkina Faso"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-581X","authenticated-orcid":false,"given":"Matthew B","family":"Laurens","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"2023092722352925800_CIT0001","volume-title":"WHO Expert Committee on Biological Standardization, Sixty-Fourth Report","author":"World Health Organization & WHO Expert Committee on Biological Standardization","year":"2014"},{"key":"2023092722352925800_CIT0002","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2023092722352925800_CIT0003","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.3389\/fimmu.2019.02582","article-title":"IgA and IgG1 specific to Vi polysaccharide of Salmonella Typhi correlate with protection status in a typhoid fever controlled human infection model","volume":"10","author":"Dahora","year":"2019","journal-title":"Front Immunol"},{"key":"2023092722352925800_CIT0004","doi-asserted-by":"crossref","first-page":"e20201116","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin","year":"2021","journal-title":"J Exp Med"},{"key":"2023092722352925800_CIT0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijid.2021.05.061","article-title":"Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: a randomized controlled phase 2 trial","volume":"108","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023092722352925800_CIT0006","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ijid.2020.10.103","article-title":"Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso","volume":"102","author":"Sirima","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2023092722352925800_CIT0007","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023092722352925800_CIT0008","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"key":"2023092722352925800_CIT0009","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"N Engl J Med"},{"key":"2023092722352925800_CIT0010","doi-asserted-by":"crossref","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2023092722352925800_CIT0011","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1016\/j.vaccine.2021.07.073","article-title":"Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7 years following primary vaccination of children &lt;2 years of age with, or without, a booster vaccination","volume":"39","author":"Vadrevu","year":"2021","journal-title":"Vaccine"},{"key":"2023092722352925800_CIT0012","doi-asserted-by":"crossref","first-page":"e1326","DOI":"10.1016\/S2214-109X(22)00275-3","article-title":"Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial","volume":"10","author":"Nampota-Nkomba","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2023092722352925800_CIT0013","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piad058\/51551290\/piad058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/12\/9\/513\/51774150\/piad058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/12\/9\/513\/51774150\/piad058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T22:36:14Z","timestamp":1695854174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/12\/9\/513\/7244101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,17]]},"published-print":{"date-parts":[[2023,9,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piad058","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,8,17]]}}}